Radiation oncology firm Sirtex Medical has made an investment in BlackSwan Vascular, a company developing therapies for endovascular embolization.
Sirtex's investment supports BlackSwan's clinical trials for BlackSwan Lava, a liquid embolic system for a peripheral vascular clinical indication. The agreement also includes an option for Sirtex to acquire BlackSwan.
If cleared by the U.S. Food and Drug Administration, the product would be the first system that optimizes radiopacity, reduces preparation time and controls delivery, and is available in two viscosities for use in the treatment of peripheral vascular diseases, according to Sirtex.
